Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00062049 · ClinicalTrials.gov registry record · Phase 1
Interleukin-7 in Treating Patients With Refractory Solid Tumors
A Phase 1 study, sponsored by National Institutes of Health Clinical Center (CC).
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT00062049 is a Phase 1 study that has completed, run by National Institutes of Health Clinical Center (CC). The registered enrollment target is 30 participants.
The verdict
NCT00062049, a Phase 1 study, has completed, sponsored by National Institutes of Health Clinical Center (CC).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
RATIONALE: Interleukin-7 may stimulate a person's white blood cells to kill tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of interleukin-7 in treating patients with refractory solid tumors.
Interventions
- BIOLOGICAL recombinant interleukin-7
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2003-04 |
| Est. Completion | 2011-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00062049
The ClinicalTrials.gov registry entry for NCT00062049 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institutes of Health Clinical Center (CC), which has 338 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which recombinant interleukin-7 is the first listed.
NCT00062049 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00062049 about?
NCT00062049 is a clinical study titled "Interleukin-7 in Treating Patients With Refractory Solid Tumors". RATIONALE: Interleukin-7 may stimulate a person's white blood cells to kill tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of interleukin-7 in treating patients with refractory solid tumors.
What is the current status of trial NCT00062049?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2003-04. Estimated completion is 2011-05.
What interventions are being tested in trial NCT00062049?
The interventions under investigation include: recombinant interleukin-7 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00062049?
This trial is sponsored by National Institutes of Health Clinical Center (CC), which has 338 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.